NTRB: צמיחה צפויה ברווח למניה לשנה הבאה Nutriband Inc.

Nutriband Inc. occupies a narrow niche in the development of transdermal systems designed to prevent opioid abuse. The company's annual EPS forecast reflects current market expectations, with the value fixed at 0.00. Growth potential is driven by patents for the Aversa technology, which ensures the safety of severe pain therapy, and the brand's high authority within the medical community.
NTRB (Nutriband Inc): פילוחים אנליטיים ודוחות לפי אינדיקטורים

This indicator measures the analysts' consensus forecast for the change in earnings per share for the next fiscal year relative to current values. The trend of the forward EPS n+1 growth rate reflects the reallocation of institutional capital based on expected business profitability. For Nutriband Inc. (NTRB), this metric is critical as it monetizes unique patent barriers in the field of transdermal systems, shielding the company from competition.